MG004: A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of ROZANOLIXIZUMAB in Adult Patients with Generalized Myasthenia Gravis

Grants and Contracts Details

StatusFinished
Effective start/end date10/29/19 → 9/15/21

Funding

  • Parexel International LLC: $144,851.00